DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
This action is in response to papers filed 7/08/2026.
Applicant’s election without traverse of Group II in the reply filed on 3/9/2026 is acknowledged.
Claims 20, 42-58 are pending. Claims 1-19, 21-41 have been cancelled.
The following rejections are newly applied as necessitated by amendment.
The following action is final.
Withdrawn Objections and Rejections
The objection to the specification and the claims made in the previous office action are withdrawn based upon amendments to the claims and specification.
The 35 USC 112b, 35 USC 102, 35 USC 103 rejections made in the previous office action are withdrawn based upon amendments to the claims.
Claim Rejections - 35 USC § 112
The following is a quotation of 35 U.S.C. 112(b):
(b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention.
The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph:
The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.
Claims 20, 42-58 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention.
Claims 20, 42-58 are indefinite over steps b to c of claim 20. In particular the sample comprises cells, particles or nuclei however in step c, the sample requires that cell, particular or nucleic to mix in the pooled sample. However, the split doesn’t require that the cells, particles or nucleic are split, rather that the sample is split. As such it is not clear if the claim is intending that the split sample has only particular cells, particles or nuclei.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
This application currently names joint inventors. In considering patentability of the claims the examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention(s) absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the examiner to consider the applicability of 35 U.S.C. 102(b)(2)(C) for any potential 35 U.S.C. 102(a)(2) prior art against the later invention.
Claim(s) 20,42-46 and 49-50 is/are rejected under 35 U.S.C. 103 as being unpatentable over O’Huallachain et al.(Communications Biology May 7, 2020 Vol 3 p 1-19 cited on IDS) in view of Ismagilov et al. (US Patent Application Publication 2019/0144854 May 16, 2019).
With regard to claim 20, O’Huallachian et al. teaches a split and pool approach (p 3). O’Huallachian teaches adding cDNA with an annealed anchor (e.g. indexing sample). O’Huallachian teaches splitting into multiple compartments and then combining the cells back into a pool (p. 3). O’Huallachian et al. teaches that these steps can be repeated up to 4 times (figure 1 p. 3-4). However O’Huallachian et al. does not teach that switching the device to pooling and splitting steps into multiple compartments.
With regard to claim 42, O’Huallachian teaches a method of loading the samples onto a device in the splitting state (Figure 1 part C).
With regard to claims 43-44, O’Huallachian teaches a method of switching a device from a pooing state (e.g. a tube) to a plate (splitting) and then back again to collect the samples (figure 1).
With regard to claim 45, O’Huallachian teaches that the sample comprises cells and that cDNA is labeled (figure 1).
With regard to claim 46, O’Huallachian teaches ligation (p. 9).
With regard to claim 48, O’Huallachian teaches that the subunit is a nucleotide (figure 7a).
With regard to claim 49, O’Huallachian teaches splitting into at least 96 wells (figure 1).
With regard to claim 50, O’Huallachian teaches 50 ul (p. 15 last parpaghra).
With regard to claim 20, Ismagilov et al. teaches a methodology of split and pool barcoding wherein the samples are split and pooled based upon magnetic force into wells on the device (para 221). Therefore the device can pool samples and then split them on the device by turning on and off the magnetic force.
Therefore it would be prima facie obvious that one can use any of the finite number of devices to split and pool samples to barcode, including using a device that uses magnetics to pool and split as taught by Ismagilov et la.
Claim(s) 47 is/are rejected under 35 U.S.C. 103 as being unpatentable over O’Huallachain et al.(Communications Biology May 7, 2020 Vol 3 p 1-19) and Ismagilov et al. (US Patent Application Publication 2019/0144854 May 16, 2019) as applied to claims 20,42-46,49-50 and in view of Shalek et al. (US Patent Application Publication 2019/0093154 March 28, 2019).
O’Huallachian et al. and Ismagilov et al. teaches a split and pool approach. O’Huallachian teaches adding cDNA with an annealed anchor (e.g. indexing sample). O’Huallachian teaches splitting into multiple compartments and then combining the cells back into a pool (p. 3). The limitation of a “device that is capable of being switched back and forth” can be broadly interpreted as the whole system of O’Huallachian.
However, O’Huallachian et al. does and Ismagilov et al. do not teach a bioorthogonal addition reaction.
With regard to claim 47, Shalek et al. teaches a pool and switch method wherein the tags are labeled biorthogonal reaction (para 159).
Therefore it would be prima facie obvious at the time of the effective filling date to modify O’Huallachian et al. and Ismagilov et al. to use the linker reaction of Shalek et al. in order to provide a barcode that is covalently liked to the sample. Shalek et al. teaches that this linkage is performed using a bioorthongnal reaction (para 159) and as such teaches the method of one of the finite number of linkage methods to attach a tag. The ordinary artisan would have a reasonable expectation of one of the known attachment assays to link a tag onto the targets of interest in O’Huallachian and Ismagilov et al..
Claim(s) 51-52 is/are rejected under 35 U.S.C. 103 as being unpatentable over O’Huallachain et al. (Communications Biology May 7, 2020 Vol 3 p 1-19) and Ismagilov et al. (US Patent Application Publication 2019/0144854 May 16, 2019) as applied to claims 20,42-46,49-50 and in view of Gunderson et al. (US Patent Application 2018/0273933 September 27, 2018).
O’Huallachian et al. and Ismagilov et al. teaches a split and pool approach. O’Huallachian teaches adding cDNA with an annealed anchor (e.g. indexing sample). O’Huallachian teaches splitting into multiple compartments and then combining the cells back into a pool (p. 3). The limitation of a “device that is capable of being switched back and forth” can be broadly interpreted as the whole system of O’Huallachian.
However, O’Huallachian et al. does not teach a device connected by channels and a dam.
With regard to claim 51, Gunderson et al. teaches a multi compartment plate that are connected by channels (para 4-6, Figure 1, 60, 125). Gunderson et al. teaches that the plate can have a hydrogel which can be dissolved (para 21) and as such teach fluidically connected. Gunderson teaches that this hydrogel has wells and as such these depressions can be considered having a dam element that blocks the hydrogel between the wells.
With regard to claim 52, the hydrogel can comprise with capillary tubes (21 and 60), as the hydrogel is a flexible membrane it would be considered a flexible material.
Therefore it would be prima facie obvious to one of ordinary skill in the arts at the time of the effective filing date to modify the support membrane of O’Huallachian and Ismagilov et al. to use the support of Gunderson et al. The ordinary artisan would be motivated to use the device of Gunderson et al. as the device can be used to split and pool samples on one device.
Conclusion
No claims are allowed.
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to KATHERINE D SALMON whose telephone number is (571)272-3316. The examiner can normally be reached 9-530.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Wu Cheng (Winston) Shen can be reached at 5712723157. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/KATHERINE D SALMON/Primary Examiner, Art Unit 1682